Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | PRSS8 | Q16651 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5946038 | 0.84 | ATM (0.40) | ATMCTSKCTSLCTSBITGB3 | |
| SCHEMBL5460207 | 0.84 | ATM (0.40) | ATMCTSKCTSLCTSBITGB3 | |
| SCHEMBL5460212 | 0.84 | ATM (0.40) | ATMCTSKCTSLCTSBITGB3 | |
| SCHEMBL5460216 | 0.84 | ATM (0.40) | ATMCTSKCTSLCTSBITGB3 | |
| SCHEMBL7260210 | 0.83 | ATM (0.35) | ATMCTSKCTSLCTSBCTSS | |
| SCHEMBL5703665 | 0.83 | ATM (0.35) | ATMCTSKCTSLCTSBCTSS | |
| SCHEMBL7260207 | 0.81 | PTGER4 (0.43) | CTSKCTSLCTSBCTSSITGB3 | |
| SCHEMBL5704088 | 0.80 | PPARG (0.33) | CTSK | |
| SCHEMBL2398018 | 0.74 | KYNU (0.57) | CTSKCTSLCTSBCTSSCYP3A4 | |
| SCHEMBL2396183 | 0.74 | KYNU (0.57) | CTSKCTSLCTSBCTSSCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004000838-A1 | PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |